Successful Allogeneic Hematopoietic Stem Cell Transplantation for a Patient with Very Severe Aplastic Anemia During Active Invasive Fungal Infection
10.15264/cpho.2016.23.1.57
- Author:
Euri SEO
1
;
Hyeri KIM
;
Kyung Nam KOH
;
Ho Joon IM
;
Jong Jin SEO
Author Information
1. Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea. pedkkn@gmail.com
- Publication Type:Case Report
- Keywords:
Aplastic anemia;
Hematopoietic stem cell transplantation;
Invasive pulmonary aspergillosis
- MeSH:
Anemia, Aplastic;
Antilymphocyte Serum;
Cyclophosphamide;
Female;
Fever;
Granulocytes;
Hematopoiesis;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells;
Humans;
Infant;
Invasive Pulmonary Aspergillosis;
Mortality;
Neutrophils;
Siblings;
Tissue Donors
- From:Clinical Pediatric Hematology-Oncology
2016;23(1):57-60
- CountryRepublic of Korea
- Language:English
-
Abstract:
Allogeneic hematopoietic stem cell transplantation (HSCT) may not be considered feasible in a patient with active fungal infection due to transplant-related mortality. We report a case of HSCT performed on a 6-month-old girl, who was diagnosed with very severe aplastic anemia (vSAA) at the age of 2 months, during active invasive pulmonary aspergillosis (IPA). Despite receiving continuous antifungal treatment and multiple granulocyte infusions, her IPA was aggravated. She underwent allogeneic HSCT from a matched sibling donor using conditioning regimen of fludarabine, reduced dose of cyclophosphamide, and anti-thymocyte globulin (ATG) during IPA. After neutrophil engraftment, fever subsided and IPA improved. She was continued on voriconazole for 7 months after HSCT. She is alive with normal hematopoiesis 4 years post-transplant. Our report suggests that allogeneic HSCT using conditioning regimen of fludarabine, reduced dose of cyclophosphamide, and ATG can be a feasible option for the patients with vSAA even during active fungal infection.
